Proteogenomic Landscape of Breast Ductal Carcinoma Reveals Tumor Progression Characteristics and Therapeutic Targets

Proteogenomic Landscape of Breast Ductal Carcinoma Reveals Tumor Progression Characteristics and Therapeutic Targets

Abstract Multi‐omics studies of breast ductal carcinoma (BRDC) have advanced the understanding of the disease's biology and accelerated targeted therapies. However, the temporal order of a series of biological events in the progression of BRDC is still poorly understood. A comprehensive proteog...

Full description

Saved in:
Bibliographic Details
Main Authors: Ganfei Xu, Juan Yu, Jiacheng Lyu, Mengna Zhan, Jie Xu, Minjing Huang, Rui Zhao, Yan Li, Jiajun Zhu, Jinwen Feng, Subei Tan, Peng Ran, Zhenghua Su, Xinhua Liu, Jianyuan Zhao, Hongwei Zhang, Chen Xu, Jun Chang, Yingyong Hou, Chen Ding
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Advanced Science
Subjects:
AKR1C1
breast ductal carcinoma
progression
proteogenomics
sterol hormone receptor
Online Access:https://doi.org/10.1002/advs.202401041
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Multi‐omics studies of breast ductal carcinoma (BRDC) have advanced the understanding of the disease's biology and accelerated targeted therapies. However, the temporal order of a series of biological events in the progression of BRDC is still poorly understood. A comprehensive proteogenomic analysis of 224 samples from 168 patients with malignant and benign breast diseases is carried out. Proteogenomic analysis reveals the characteristics of linear multi‐step progression of BRDC, such as tumor protein P53 (TP53) mutation‐associated estrogen receptor 1 (ESR1) overexpression is involved in the transition from ductal hyperplasia (DH) to ductal carcinoma in situ (DCIS). 6q21 amplification‐associated nuclear receptor subfamily 3 group C member 1 (NR3C1) overexpression helps DCIS_Pure (pure DCIS, no histologic evidence of invasion) cells avoid immune destruction. The T‐cell lymphoma invasion and metastasis 1, androgen receptor, and aldo‐keto reductase family 1 member C1 (TIAM1‐AR‐AKR1C1) axis promotes cell invasion and migration in DCIS_adjIDC (DCIS regions of invasive cancers). In addition, AKR1C1 is identified as a potential therapeutic target and demonstrated the inhibitory effect of aspirin and dydrogesterone as its inhibitors on tumor cells. The integrative multi‐omics analysis helps to understand the progression of BRDC and provides an opportunity to treat BRDC in different stages.
ISSN:2198-3844

Similar Items